2DS1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: Killer cell immunoglobulin-like receptor 2DS1, transcript variant X1

NCBI ID: G105379662

Killer cell immunoglobulin-like receptor 2DS1, transcript variant X1

Other Name(s): Killer cell immunoglobulin-like receptor 2DS1, transcript variant X2 | Killer cell immunoglobulin-like receptor 2DS1 (isoform X2) | LOC105379662 variant X1 | Killer cell immunoglobulin-like receptor 2DS1 (isoform X1) | LOC105379662 variant X2 | KIR2DL1 protein

2DS1: A Potential Drug Target and Biomarker for Various Diseases

Killer cell immunoglobulin-like receptor 2DS1, transcript variant X1 (Killer cell immunoglobulin-like receptor 2DS1, transcript variant X2) is a protein that is expressed in various tissues, including the brain, spleen, heart, and testes. It is a member of the immunoglobulin-like receptor (ILR) family and is involved in the immune response.

The 2DS1 gene has four exons, and it encodes a protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is responsible for the protein's ability to interact with ligand, while the transmembrane domain is responsible for the protein's ability to span the membrane and interact with intracellular signaling molecules. The intracellular domain is responsible for the protein's ability to interact with other proteins and for the signaling pathways that are involved in its function.

2DS1 is a potent inhibitor of the enzyme PKC, which is involved in a variety of cellular processes, including cell signaling, DNA damage repair, and inflammation. The inhibition of PKC by 2DS1 causes a decrease in the production of pro-inflammatory cytokines, such as IL-1??, and an increase in the production of anti-inflammatory cytokines, such as IL-10.

2DS1 is also known as Killer cell immunoglobulin-like receptor 2DS1, transcript variant X2. This name comes from its location on the X chromosome, where it is located on the 2nd chromosome.

2DS1 has been shown to be involved in a variety of biological processes, including immune responses, inflammation, and cell signaling. For example, studies have shown that 2DS1 is involved in the regulation of T cell responses, which are critical for immune defense against infections and cancer.

In addition to its role in immune responses, 2DS1 is also involved in cell signaling and has been shown to be involved in the regulation of cell proliferation, apoptosis, and angiogenesis.

Given its involvement in a variety of biological processes, 2DS1 is a potential drug target and could be used as a biomarker for a variety of diseases. For example, studies have shown that inhibiting the activity of 2DS1 has anti-inflammatory effects and may be useful in treating autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

In addition, 2DS1 has also been shown to be involved in the regulation of cancer cell growth and may be a useful target for cancer therapies. For example, studies have shown that inhibiting the activity of 2DS1 has anti-tumor effects and may be useful in treating breast cancer.

Overall, 2DS1 is a protein that is involved in a variety of biological processes and has been shown to have a variety of potential drug targets and biomarkers. Further research is needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Killer Cell Immunoglobulin-like Receptor 2DS1, Transcript Variant X1

The "Killer cell immunoglobulin-like receptor 2DS1, transcript variant X1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Killer cell immunoglobulin-like receptor 2DS1, transcript variant X1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets